Informações de Vyne Therapeutics Inc

Mais detalhes de Vyne Therapeutics Inc Empresa

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.



Código da empresaVYNE

Nome da EmpresaVyne Therapeutics Inc

Data de listagemJan 25, 2018

CEOMr. David Domzalski

Número de funcionários13

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 25

Endereço685 Route 202/206 N., Suite 301

CidadeBRIDGEWATER

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal08807

Telefone18007757936

Sitehttps://vynetherapeutics.com/

Código da empresaVYNE

Data de listagemJan 25, 2018

CEOMr. David Domzalski

Executivos da empresa Vyne Therapeutics Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

38.72K

-8.47%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

28.16K

-8.01%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Sharon Barbari

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

38.72K

-8.47%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

28.16K

-8.01%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Sharon Barbari

Independent Director

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2024

FY2023

FY2022

FY2021

FY2020

Por EmpresaUSD

Nome

Receita

Proporção

Royalty revenues

501.00K

0.00%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Royalty revenues

501.00K

0.00%

Distribuição de ações

Atualizado em: ter, 19 de ago

Investidores

Tipos de investidores

Investidores

Proporção

Cormorant Asset Management, LP

5.38%

Access Industries, Inc.

4.38%

Citadel Advisors LLC

4.08%

Acorn Capital Advisors, LLC

2.89%

Delaware Street Capital, L.L.C.

2.73%

Outro

80.53%

Investidores

Proporção

Cormorant Asset Management, LP

5.38%

Access Industries, Inc.

4.38%

Citadel Advisors LLC

4.08%

Acorn Capital Advisors, LLC

2.89%

Delaware Street Capital, L.L.C.

2.73%

Outro

80.53%

Tipos de investidores

Investidores

Proporção

Hedge Fund

22.17%

Investment Advisor

8.71%

Corporation

4.38%

Investment Advisor/Hedge Fund

1.61%

Individual Investor

1.37%

Private Equity

1.24%

Research Firm

0.59%

Venture Capital

0.22%

Outro

59.71%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

84

8.80M

34.54%

-586.92K

2025Q2

84

9.46M

56.76%

-1.30M

2025Q1

81

9.36M

56.20%

-1.38M

2024Q4

92

9.37M

63.49%

-533.87K

2024Q3

88

8.98M

61.30%

-594.32K

2024Q2

89

9.65M

66.73%

+287.65K

2024Q1

92

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

2023Q2

135

501.83K

15.37%

-314.68K

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Cormorant Asset Management, LP

1.37M

5.38%

+1.37M

--

Jun 30, 2025

Access Industries, Inc.

1.12M

4.38%

--

Feb 14, 2025

Citadel Advisors LLC

1.04M

4.08%

-60.26K

-5.48%

Jun 30, 2025

Acorn Capital Advisors, LLC

736.57K

2.89%

-49.37K

-6.28%

Jun 30, 2025

Delaware Street Capital, L.L.C.

696.47K

2.73%

--

Sep 30, 2024

Adage Capital Management, L.P.

644.13K

2.53%

+300.00K

+87.18%

Jun 30, 2025

Dafna Capital Management, LLC

636.10K

2.5%

--

Jun 30, 2025

Kennedy Capital Management LLC

570.74K

2.24%

+492.70K

+631.35%

Jun 30, 2025

The Vanguard Group, Inc.

496.30K

1.95%

+20.65K

+4.34%

Jun 30, 2025

Palo Alto Investors LP

445.43K

1.75%

--

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: dom, 2 de nov

Nome

Proporção

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Data

Tipo

Proporção

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1